Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DHEA as Augmentation in Treatment-resistant Depression
NCT07843927Phase 3Recruiting
- Sponsor
- Charité – Universitätsmedizin Berlin
- Start
- Jun 2026
- Primary completion
- Sep 2028
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in treatment-resistant depression (TRD) comparing DHEA with Placebo (2 arms). Primary endpoint: Change score in Montgomery-Asberg Depression Rating Scale at 6 weeks. Started Jun 2026; status: recruiting.
02
Drugs
dehydroepiandrosterone
03
Conditions
treatment-resistant depression (TRD)
Beyond the preview
Go deeper on NCT07843927.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07843927.